CO2022005949A2 - Métodos para tratar pénfigo mediante la administración de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo - Google Patents
Métodos para tratar pénfigo mediante la administración de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitriloInfo
- Publication number
- CO2022005949A2 CO2022005949A2 CONC2022/0005949A CO2022005949A CO2022005949A2 CO 2022005949 A2 CO2022005949 A2 CO 2022005949A2 CO 2022005949 A CO2022005949 A CO 2022005949A CO 2022005949 A2 CO2022005949 A2 CO 2022005949A2
- Authority
- CO
- Colombia
- Prior art keywords
- enenitrile
- oxetan
- pent
- pyrazolo
- piperazin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
En la presente memoria se describen métodos para tratar pénfigo en un paciente humano que lo necesita que comprenden administrar al paciente humano una dosis de al menos 400 mg de (R)-2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo (PRN1008) una vez al día (QD) o dos veces al día (BID).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962913029P | 2019-10-09 | 2019-10-09 | |
US201962942877P | 2019-12-03 | 2019-12-03 | |
PCT/US2020/054809 WO2021072095A1 (en) | 2019-10-09 | 2020-10-08 | Methods of treating pemphigus by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2022005949A2 true CO2022005949A2 (es) | 2022-07-29 |
Family
ID=73030241
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2022/0005949A CO2022005949A2 (es) | 2019-10-09 | 2022-05-06 | Métodos para tratar pénfigo mediante la administración de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo |
Country Status (13)
Country | Link |
---|---|
US (2) | US20210106583A1 (es) |
EP (1) | EP4041240A1 (es) |
JP (1) | JP2022552199A (es) |
KR (1) | KR20220079909A (es) |
CN (1) | CN115190798A (es) |
AU (1) | AU2020363873A1 (es) |
BR (1) | BR112022005575A2 (es) |
CA (1) | CA3153750A1 (es) |
CO (1) | CO2022005949A2 (es) |
IL (1) | IL291726A (es) |
MX (1) | MX2022004283A (es) |
TW (1) | TW202128172A (es) |
WO (1) | WO2021072095A1 (es) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2892900T (pt) | 2012-09-10 | 2017-11-06 | Principia Biopharma Inc | Compostos de pirazolopirimidina como inibidores de cinase |
EP3107544B1 (en) | 2014-02-21 | 2020-10-07 | Principia Biopharma Inc. | Salts and solid form of a btk inhibitor |
CA2970723C (en) | 2014-12-18 | 2023-09-05 | Principia Biopharma Inc. | Treatment of pemphigus |
MA41256B1 (fr) | 2014-12-24 | 2021-02-26 | Principia Biopharma Inc | Dosage spécifique de site d'un inhibiteur de btk |
EP3478273A1 (en) | 2016-06-29 | 2019-05-08 | Principia Biopharma Inc. | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
WO2019208805A1 (ja) * | 2018-04-27 | 2019-10-31 | 小野薬品工業株式会社 | Btk阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および/または治療剤 |
-
2020
- 2020-10-08 BR BR112022005575A patent/BR112022005575A2/pt unknown
- 2020-10-08 EP EP20797943.6A patent/EP4041240A1/en active Pending
- 2020-10-08 MX MX2022004283A patent/MX2022004283A/es unknown
- 2020-10-08 TW TW109135047A patent/TW202128172A/zh unknown
- 2020-10-08 CN CN202080083113.6A patent/CN115190798A/zh active Pending
- 2020-10-08 JP JP2022520968A patent/JP2022552199A/ja active Pending
- 2020-10-08 AU AU2020363873A patent/AU2020363873A1/en active Pending
- 2020-10-08 KR KR1020227015113A patent/KR20220079909A/ko unknown
- 2020-10-08 US US17/066,300 patent/US20210106583A1/en not_active Abandoned
- 2020-10-08 WO PCT/US2020/054809 patent/WO2021072095A1/en active Application Filing
- 2020-10-08 CA CA3153750A patent/CA3153750A1/en active Pending
-
2022
- 2022-03-27 IL IL291726A patent/IL291726A/en unknown
- 2022-05-06 CO CONC2022/0005949A patent/CO2022005949A2/es unknown
- 2022-09-30 US US17/957,073 patent/US20230158033A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2022004283A (es) | 2022-07-12 |
US20230158033A1 (en) | 2023-05-25 |
EP4041240A1 (en) | 2022-08-17 |
US20210106583A1 (en) | 2021-04-15 |
TW202128172A (zh) | 2021-08-01 |
CN115190798A (zh) | 2022-10-14 |
IL291726A (en) | 2022-05-01 |
KR20220079909A (ko) | 2022-06-14 |
BR112022005575A2 (pt) | 2022-06-21 |
WO2021072095A1 (en) | 2021-04-15 |
JP2022552199A (ja) | 2022-12-15 |
CA3153750A1 (en) | 2021-04-15 |
AU2020363873A1 (en) | 2022-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123110T1 (el) | Συνδυασμοι και τροποι χορηγησης θεραπευτικων παραγοντων και θεραπεια συνδυασμου | |
AR050418A1 (es) | Dosificacion fija de anticuerpos her | |
CY1121330T1 (el) | Συνθεσεις που περιλαμβανουν αζελαστινη και μεθοδοι χρησης αυτων | |
Simcock et al. | Follow-up and survivorship in head and neck cancer | |
Gommoll et al. | A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40–120 mg/day) in patients with major depressive disorder | |
CY1116463T1 (el) | Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης | |
EA202092154A1 (ru) | Комбинированная терапия | |
ECSP045140A (es) | Formulaciones farmacéuticas derivadas del platino | |
CL2020003101A1 (es) | Sales de sepiapterina farmacéuticamente aceptables. | |
BR112021025764A2 (pt) | Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo | |
Uchida et al. | The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets | |
EA202090242A1 (ru) | Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов | |
BR112021023110A2 (pt) | Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton | |
EA202190334A1 (ru) | Фармацевтическая лекарственная форма для перорального введения с модифицированным высвобождением | |
CO2022005949A2 (es) | Métodos para tratar pénfigo mediante la administración de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo | |
CL2021000444A1 (es) | Métodos para reducir el riesgo de diabetes en pacientes tratados por enfermedades relacionadas con el colesterol alto. | |
AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
CO2022006087A2 (es) | Métodos para el tratamiento de la trombocitopenia inmunitaria mediante la administración de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidino-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo | |
EP4282477A3 (en) | Combination comprising sildenafil for use in the treatment of osteoarthritis | |
UY38948A (es) | Régimen de dosificación para agentes anti-dll3 | |
Abdullah | THU0189 placebo effect in the treatment of rheumatoid arthritis: A systematic review and meta-analysis of randomized controlled trials | |
AR047154A1 (es) | Tratamiento del insomnio en pacientes humanos administrandoles una cantidad diaria de gaboxadol | |
MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. | |
Hamarat et al. | Rhabdomyolysis probably induced by influenza vaccine and fibrate therapy | |
Zhou et al. | Traditional Chinese medicine. |